Retatrutide: What It Is, What the Research Shows, and When You Can Get It

Retatrutide is an investigational once-weekly medication designed to activate three hormone receptors involved in appetite, glucose regulation, and energy metabolism: GLP-1, GIP, and glucagon. It is not approved by the U.S. Food and Drug Administration (FDA), cannot be prescribed by NovaGenix, and is legally available only through authorized clinical trials. This article explains what current research shows, what remains unknown, and which physician-supervised weight-loss options are available now.

Medically reviewed by Timothy W. Mackey, D.O. — Medical Director, NovaGenix · Last reviewed: June 29, 2026

What Is Retatrutide?

Retatrutide, also known by its research designation LY3437943, is an experimental medication being developed by Eli Lilly. It is a single molecule that activates three metabolic hormone receptors:

 
• GLP-1 (glucagon-like peptide-1): helps reduce appetite, supports insulin release when glucose is elevated, and slows stomach emptying.
 
• GIP (glucose-dependent insulinotropic polypeptide): contributes to insulin signaling and may complement the effects of GLP-1.
 
• Glucagon: affects liver metabolism and energy expenditure, although its overall clinical effects must be understood in the context of the complete molecule.

Semaglutide activates the GLP-1 receptor, while tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds glucagon-receptor activity, which is why researchers refer to it as a triple hormone receptor agonist.

How Does Retatrutide Work?

Retatrutide is being studied as a medication that may reduce hunger and food intake while also influencing glucose control and energy metabolism. Its three-receptor design is intended to combine complementary metabolic effects in one weekly injection. However, the mechanism alone does not establish that a medication is safe, effective, or appropriate for an individual. Those questions require completed clinical trials and regulatory review.

Why Is Retatrutide Sometimes Called “GLP-3”?

“GLP-3” is an informal and scientifically inaccurate nickname. There is no GLP-3 hormone involved. The more accurate description is triple agonist because retatrutide activates GLP-1, GIP, and glucagon receptors.

What Does the Research Show?

Clinical research has produced substantial average weight reductions, but retatrutide remains investigational. Trial results describe averages in defined research populations; they do not predict what any individual would experience.

Phase 2 Results

In a randomized Phase 2 trial published in The New England Journal of Medicine, adults with obesity or overweight and at least one weight-related condition were assigned to retatrutide at different doses or placebo. At 48 weeks, the highest-dose group had an average body-weight reduction of 24.2% under the trial’s efficacy analysis.

The most common adverse events were gastrointestinal, including nausea, diarrhea, vomiting, and constipation. These effects occurred most often during dose escalation. The Phase 2 results justified larger trials, but they did not by themselves establish long-term safety or FDA approval.

The Phase 3 TRIUMPH Program

The TRIUMPH program is a collection of large Phase 3 studies evaluating retatrutide across obesity and related conditions. Phase 3 trials are designed to confirm efficacy and characterize safety in larger populations before a manufacturer seeks regulatory approval.

In May 2026, Lilly announced topline results from TRIUMPH-1, an 80-week trial in 2,339 adults with obesity or overweight and a weight-related condition, without diabetes. In the efficacy estimand, average weight reduction at 80 weeks ranged from 19.0% at 4 mg to 28.3% at 12 mg. The treatment-regimen estimand—which includes results regardless of adherence or use of prohibited weight-management treatment—showed smaller average reductions. These topline results were announced by the manufacturer and should be interpreted alongside the full trial design and subsequent peer-reviewed publication.

TRIUMPH-4 studied adults with obesity or overweight and knee osteoarthritis. Lilly reported an average weight reduction of 28.7% at 68 weeks with 12 mg under the efficacy estimand, together with improvement in knee-pain measures. This was a specific trial population with a high average baseline BMI and osteoarthritis; its results should not be generalized to every person seeking weight treatment.

Retatrutide and Type 2 Diabetes

Retatrutide is also being studied in adults with type 2 diabetes. In the Phase 3 TRANSCEND-T2D-1 trial, Lilly reported average A1C reductions of approximately 1.7% to 2.0% across studied doses at 40 weeks, along with average weight reductions that varied by dose. These findings are important because weight response and glucose response can differ between people with and without diabetes.

Patients should not interpret diabetes-trial data as instructions to obtain or use an investigational product. The appropriate treatment of type 2 diabetes requires individualized evaluation, medication review, and ongoing monitoring by a qualified healthcare professional.

How Does Retatrutide Compare With Semaglutide and Tirzepatide?

Retatrutide activates three receptors, compared with two for tirzepatide and one for semaglutide, but receptor count alone does not prove clinical superiority.

 
• Semaglutide: GLP-1 receptor agonist; FDA-approved products exist for specific diabetes and chronic weight-management indications.
 
• Tirzepatide: GIP and GLP-1 receptor agonist; FDA-approved products exist for specific diabetes and chronic weight-management indications.
 
• Retatrutide: GIP, GLP-1, and glucagon receptor agonist; investigational and not FDA-approved.

There has not yet been a completed head-to-head trial establishing retatrutide’s comparative efficacy against semaglutide or tirzepatide. Percentages reported for these medications come from separate trials with different populations, durations, doses, endpoints, adherence assumptions, and statistical methods. Side-by-side percentages are useful for context but cannot be treated as a direct comparison.

A trial comparing retatrutide with tirzepatide is registered, but until comparative results are available, claims that one is definitively “better” than another go beyond the evidence.

What Are the Known Side Effects?

The most commonly reported side effects have been gastrointestinal and generally resemble those observed with other incretin-based therapies. They include:

 
• Nausea
 
• Diarrhea
 
• Constipation
 
• Vomiting
 
• Decreased appetite or early fullness

Rates differed by study and dose, and symptoms commonly occurred during escalation. Some participants discontinued treatment because of adverse events. Phase 3 studies have also reported dysesthesia—abnormal skin sensations such as tingling, burning, or increased sensitivity. Many reported cases were mild to moderate, but this signal remains important as the safety database develops.

Other clinically important risks may emerge or become clearer as trials continue and regulators review complete datasets. Topline announcements are not a substitute for an FDA-approved prescribing label, which would define indications, contraindications, warnings, precautions, and dosing if the medication is approved.

Who Should Not Take GLP-1 Class Medications?

Eligibility depends on the specific medication and the individual’s medical history. Approved incretin medications carry important warnings and contraindications, and clinical trials for retatrutide have excluded certain participants. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) is a key concern in this medication class.

Other issues requiring careful medical review may include pregnancy, a history of pancreatitis, severe gastrointestinal disease, gallbladder disease, kidney problems, diabetes medications that can cause hypoglycemia, and other conditions or medications affecting treatment safety. This is not a complete list, and retatrutide does not yet have an FDA-approved label.

Dosing Used in Clinical Trials

There is no FDA-approved retatrutide dosing schedule. The following schedule describes dose escalation used in major clinical trials; it is not a treatment recommendation:

 
• Weeks 1–4: 2 mg once weekly
 
• Weeks 5–8: 4 mg once weekly
 
• Weeks 9–12: 6 mg once weekly when assigned to a higher target dose
 
• Weeks 13–16: 9 mg once weekly when assigned to a higher target dose
 
• Target doses studied: up to 12 mg once weekly, depending on the trial arm

NovaGenix DOES NOT recommend taking this medication until it receives FDA approval. The recommended dosing schedule is based on current research and does in no way reflect our position of it being safe, legal or an endorsement to use.

Publishing a research protocol does not make that protocol appropriate for self-treatment. Products sold online as “research use only” cannot be assumed to contain authentic retatrutide or a reliable dose.

What Else May Improve Beyond Weight?

Trials have reported changes in cardiometabolic measures such as blood pressure, triglycerides, non-HDL cholesterol, insulin sensitivity, and glycemic control. Some research has also examined liver fat and conditions associated with obesity, including knee osteoarthritis and obstructive sleep apnea.

These outcomes matter because obesity is a chronic disease connected to cardiovascular, metabolic, musculoskeletal, and liver health. Still, an improvement observed in a trial population does not establish that retatrutide is appropriate for a particular patient or that every outcome will improve to the same degree.

Substantial weight loss can also include loss of lean mass. With any medically supervised weight-loss program, clinicians may discuss protein intake, resistance exercise, hydration, and monitoring based on the patient’s health, mobility, and treatment plan. NovaGenix has additional educational guidance on preserving muscle during GLP-1 therapy.

If You Are on Testosterone Therapy

No completed clinical trial has established a specific retatrutide protocol for patients receiving testosterone replacement therapy. Significant changes in weight, insulin sensitivity, sleep, and body composition can affect symptoms, hormone metabolism, and medication needs.

Patients using an approved weight-management medication while on testosterone replacement therapy should continue physician-directed follow-up and laboratory monitoring. Treatment decisions may consider total and free testosterone, estradiol, hematocrit, metabolic markers, symptoms, and other individualized factors.

When Will Retatrutide Be Available?

No confirmed public-availability date has been announced. As of the review date of this article, retatrutide remains in Phase 3 development. Availability would depend on completion of the clinical program, submission of evidence to regulators, FDA review, and approval of a specific indication and prescribing information.

A successful clinical trial does not automatically make a drug legal to prescribe. Regulatory agencies review the complete evidence, including safety, efficacy, manufacturing quality, labeling, and risk-management considerations.

Can NovaGenix Prescribe Retatrutide?

No. NovaGenix cannot prescribe, dispense, compound, or offer retatrutide while it remains an unapproved investigational drug. NovaGenix does not maintain a retatrutide waitlist and does not endorse products sold outside authorized clinical research.

Why Should Patients Avoid “Research Peptide” Sellers?

Anything sold directly to consumers as retatrutide is not an FDA-approved medication. Lilly states that retatrutide is legally available only through its authorized clinical trials. Products from unregulated websites may contain too much or too little active ingredient, a different ingredient, contaminants, or nonsterile material.

Labels such as “research use only” do not make a product safe or legal for human use. The FDA has issued warnings involving illegal online drug sales, and patients should not rely on online reviews, certificates posted by a seller, or social-media claims as proof of identity, purity, or sterility.

What NovaGenix Can Help With Today

NovaGenix offers physician-supervised medical weight-loss programs using options that are currently available and legally prescribable when medically appropriate. Depending on a patient’s health history, laboratory results, goals, and physician evaluation, those options may include semaglutide, tirzepatide, nutrition and activity guidance, and ongoing monitoring.

Availability does not mean a medication is right for everyone. A personalized evaluation is intended to identify appropriate options, contraindications, realistic expectations, and a monitoring plan—not to guarantee a prescription or a particular result.

Frequently Asked Questions

Is Retatrutide FDA Approved?

No. Retatrutide is an investigational medication in Phase 3 clinical trials and is not approved by the FDA or available for routine prescribing.

Can I Buy Retatrutide Online?

No legitimate FDA-approved retatrutide product is available for consumers to buy online. Products marketed as retatrutide outside authorized clinical trials are unapproved and may be illegal, contaminated, incorrectly dosed, or made with a different ingredient.

Is Retatrutide the Same as Tirzepatide?

No. Tirzepatide activates GIP and GLP-1 receptors and has FDA-approved products for specific indications. Retatrutide additionally activates the glucagon receptor and remains investigational.

Is Retatrutide Better Than Semaglutide or Tirzepatide?

That has not been established in a completed head-to-head trial. Results reported across separate studies cannot be compared as though the medications were tested in the same population under the same conditions.

What Is the Retatrutide Dosing Schedule?

There is no approved dosing schedule. Clinical trials generally started at 2 mg once weekly and increased the dose every four weeks toward assigned target doses, but those research protocols are not instructions for self-treatment.

When Will Retatrutide Be Available?

No confirmed date is available. Public availability depends on completion of clinical development, regulatory submission, FDA review, and approval.

About NovaGenix

NovaGenix Health & Wellness is a physician-led hormone and medical weight-loss clinic at 609 N. Hepburn Ave., Suite 106, Jupiter, FL 33458. Timothy W. Mackey, D.O., serves as Medical Director. Call 561-277-8260 to learn about currently available, physician-supervised options.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Retatrutide has not been approved by the FDA, and NovaGenix does not prescribe or offer it. Do not start, stop, obtain, or change any medication based on this article. Consult a qualified healthcare professional for advice based on your medical history and current treatment.

‍